Artes Biotechnology

Overview
Biosimilars?
Product stageSegments
Early
?
Contract Development and Manufacturing Organizations, Technology and Support Service Providers
?

ARTES Biotechnology is a pharmaceutical contract research organization specializing in microbial process development and technology transfer for the pharmaceutical industry. The company focuses on developing biopharmaceutical and vaccine production processes for global pharmaceutical and biotech industries. ARTES offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli) expression platforms, along with lab-scale up- and downstream process development. The company also provides non-GMP bulk material (API) for activity and toxicity tests, technology transfer to cGMP facilities, and scale-up support.

ARTES' flagship technology is METAVAX, a virus-like particle (VLP) antigen presentation platform combined with proprietary yeast expression technology. This platform is designed for the development of effective, safe, and affordable vaccines. METAVAX is applicable for large and multimeric antigens and can create chimeric VLPs. The company received a new EU-based patent grant for METAVAX in August 2017, strengthening its technology portfolio. ARTES has also enhanced its VLP-based vaccine platform for veterinary applications through the "Plurivax" project, funded by the German Federal Ministry of Education and Research.

In October 2014, ARTES Biotechnology joined forces with instrAction and Q-Biologicals to form a consortium for developing veterinary vaccines. This collaboration aimed to simplify and optimize VLP production processes for veterinary applications, focusing on cost-effectiveness and promptness. The resulting platform was intended to be the first of its kind in veterinary applications, potentially reducing the need for antibiotic treatment in food animals.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Langenfeld DEU
Founded year:
2002
Employees:
11-50
IPO status:
Private
Total funding:
-
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.